Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain.
Trimesta in relapsing-remitting multiple sclerosis patients (Phase II)
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
Oxidative modification of serum proteins in multiple sclerosis.
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
The two faces of neuromyelitis optica.
UCSF Neuroimmunology Seminar
Toxicity of Teriflunomide in Aryl Hydrocarbon Receptor Deficient Mice.
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels.
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.
Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.
Uhthoff's phenomena in MS-clinical features and pathophysiology.
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart.
Arzerra
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Biogen Idec's long-acting beta interferon moves ahead in MS

Pages